Experimental OTC drug trial halted early
Disease control
Terminated
This study tested a new medicine called ARCT-810 in people aged 12 to 65 with OTC deficiency, a rare genetic disorder that causes dangerous ammonia buildup. The goal was to see if the drug is safe and how the body processes it. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:24 UTC